A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer

Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to...

Descripción completa

Detalles Bibliográficos
Autores principales: Alameddine, Zakaria, Niazi, Muhammad Rafay Khan, Rajavel, Anisha, Behgal, Jai, Keesari, Praneeth Reddy, Araji, Ghada, Mustafa, Ahmad, Wei, Chapman, Jahangir, Abdullah, Terjanian, Terenig O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605202/
https://www.ncbi.nlm.nih.gov/pubmed/37887569
http://dx.doi.org/10.3390/curroncol30100669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605202/
https://www.ncbi.nlm.nih.gov/pubmed/37887569
http://dx.doi.org/10.3390/curroncol30100669

Ejemplares similares